Questions & answers

Does this programme prove that psychosis can be prevented?

No. Prevention of psychosis is the mission and research question. It is not presented here as an established result for NWPT’s candidate.

What is NWPT-SM32300?

Company materials describe it as a 300 mg CBD micellar-emulsion softgel under investigation. Detailed product claims will follow only when supporting documentation is ready for public use.

Is cannabidiol already proven for CHR-P?

CBD has been studied in various contexts, but other products’ data are not NWPT-SM32300 data. Any claims for this programme must rest on evidence generated with this formulation under appropriate protocols.

Will community members decide the trial design?

No. Protocol, dose, endpoints, eligibility, safety, and regulatory submissions remain with the pharmaceutical sponsor and independent clinical oversight — not community or token votes.

Where can clinicians or researchers ask scientific questions?

Use the press and general contact channel on this site for routing. This is not a diagnosis service, trial enrolment portal, or medical advice line.

Is this a DAO I can join and invest in on this website?

No — not as a live invest product on this site. “NW PharmaTech DAO” may appear as an informal label for exploring DeSci-style support. DeSci / DAO language describes coordination and open-science ambition; what is live, proposed, or undecided is labelled on related pages. There is no live investment, token sale, or wallet connection here. Community ≠ investment rights.

Is NWPharmaTech DAO a live investment product?

“NW PharmaTech DAO” is an informal label for exploring how DeSci infrastructure might support programme financing. It does not mean a token is for sale, that a DAO legal entity already exists, or that community members own NWPT or control clinical decisions.

What is DeSci doing here?

We are exploring whether new capital constituencies and transparent programme financing can support rigorous CHR-P research — without weakening pharmaceutical governance. We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process. Community ≠ investment rights.

Will tokenholders decide the clinical trial?

No. Clinical decisions remain with the pharmaceutical sponsor and independent scientific and ethical oversight.

Can I invest or buy tokens on this website?

No. This site does not accept investments, subscriptions, payments, or token purchases. Any DeSci-related labels describe a proposed approach to communities of support — not a live investment product on this website.

How could programme financing work?

We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.

If financing proceeds, it would support defined CHR-P programme economics through a dedicated programme vehicle — not ownership of NWPharmaTech, the medicine, patient data, or clinical decisions. Terms are not offered on this site.

Why involve DeSci-aware capital?

Early-intervention research is important and often hard to fund through usual biotech channels. We are exploring whether new communities of support — alongside specialist life-sciences capital — can help resource the programme while NWPharmaTech remains pharmaceutical sponsor.

What does the approximately $10 million figure mean?

It is a planning target for catalytic programme funding — not money already raised, not a validated trial budget, not a claim that capital fully funds the Phase 2B trial, and not a priced offer on this website.

What is available now versus being developed?

Available now: programme information, an educational Scenario explorer, and the Updates hub. Email registration for programme news is coming soon — see Updates or Contact meanwhile (news only, not an investment waitlist).

We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.

There is no Invest button, no eligibility decision, and no liquidity here. Financing questions are enquiries only.